| Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Gastroenterology 158 (8), 2180-2194, 2020 | 200 | 2020 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 164 | 2022 |
| Treatment steps, surgery, and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-Epicom inception cohort Z Vegh, J Burisch, N Pedersen, I Kaimakliotis, D Duricova, M Bortlik, ... Journal of Crohn's and Colitis 9 (9), 747-753, 2015 | 45 | 2015 |
| Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Hepatology 66 (1), S256-S257, 2017 | 34 | 2017 |
| Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection RMF Yuen, E Berliba, YJ Kim, JA Holmes, YS Lim, SI Strasser, ... The Annual Meeting of the American Association for the Study of Liver …, 2020 | 19 | 2020 |
| Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis S Danese, BG Levesque, BG Feagan, A Jucov, BR Bhandari, RK Pai, ... Alimentary Pharmacology & Therapeutics 55 (4), 401-411, 2022 | 18 | 2022 |
| Safety, tolerability, and antiviral activity of the siRNA VIR-2218 in combination with the investigational neutralizing monoclonal antibody VIR-3434 for the treatment of … E Gane, A Jucov, M Dobryanska, KT Yoon, TH Lim, A Arizpe, D Cloutier, ... Hepatology 76, S18-S19, 2022 | 15 | 2022 |
| Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression RMF Yuen, E Berliba, W Sukeepaisarnjaroen, S Strasser, P Tangkijvanich, ... The International Liver Congress 2021 (ILC 2021), 2021 | 15 | 2021 |
| Analysis of HBsAg Immunocomplexes and cccDNA activity during and persisting after NAP‐based therapy M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology Communications 5 (11), 1873-1887, 2021 | 13 | 2021 |
| Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: ongoing follow-up results from the REP 401 study M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Age (average/median) 36, 36, 2019 | 13 | 2019 |
| Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and … A Vaillant, M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 68, S517, 2018 | 13 | 2018 |
| HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology communications 6 (8), 1870-1880, 2022 | 12 | 2022 |
| Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with chronic hepatitis B (CHB) EJ Gane, RMF Yuen, A Jucov, K Le, C Westland, C Schwabe, K Agarwal, ... Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021 …, 2021 | 12 | 2021 |
| Benefit of transaminase elevations in establishing functional cure of HBV infection during NAP‐based combination therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Viral Hepatitis 28 (5), 817-825, 2021 | 11 | 2021 |
| Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naïve … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 64 (6), 1122A-1123A, 2016 | 9 | 2016 |
| Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects MF Yuen, E Berliba, W Sukeepaisarnjaroen, J Holmes, A Leerapun, ... Journal of Hepatology 77, S876-S877, 2022 | 8 | 2022 |
| Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B … EJ Gane, C Schwabe, E Berliba, P Tangkijvanich, A Jucov, N Ghicavii, ... Journal of Antimicrobial Chemotherapy 77 (4), 1102-1110, 2022 | 8 | 2022 |
| Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and … M Bazinet, M Anderson, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 73, S142, 2020 | 8 | 2020 |
| A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects E Berliba, A Jucov, SS Good, A Moussa, K Pietropaolo, X Zhou, ... Journal of Hepatology, 2020 | 8 | 2020 |
| Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B. Poster Presentation (SAT835) RMF Yuen, K Agarwal, EJ Gane, A Jucov, C Schwabe, JQ Niu, JL Hou, ... The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology, 2022 | 7 | 2022 |
